March 31 (Reuters) - Palvella Therapeutics Inc PVLA.O:
PALVELLA THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
PALVELLA THERAPEUTICS - NDA FOR QTORIN RAPAMYCIN FOR TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS ON TRACK FOR PLANNED SUBMISSION IN H2 2026
PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN RAPAMYCIN FOR CUTANEOUS VMS PLANNED FOR 2H 2026
PALVELLA THERAPEUTICS INC - PHASE 2 TRIAL OF QTORIN RAPAMYCIN FOR ANGIOKERATOMAS PLANNED FOR Q2 2026